Pyxis Oncology (PYXS) Change in Accured Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has reported Change in Accured Expenses for 6 consecutive years, with $552000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 120.54% year-over-year to $552000.0; the TTM figure through Dec 2025 stood at -$2.8 million (down 69.04% YoY), while the FY2025 annual figure was -$2.8 million, down 69.04% from the prior year.
• Change in Accured Expenses eased to $552000.0 in Q4 2025 per PYXS's latest filing, from $1.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.5 million in Q1 2022 and bottomed at -$13.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$77350.0 across 5 years, with a median of $464500.0 in 2021.
• On a YoY basis, Change in Accured Expenses climbed as much as 2246.64% in 2022 and fell as far as 2762.07% in 2022.
• Pyxis Oncology's Change in Accured Expenses stood at $1.9 million in 2021, then soared by 227.54% to $6.3 million in 2022, then plunged by 157.99% to -$3.7 million in 2023, then advanced by 26.62% to -$2.7 million in 2024, then soared by 120.54% to $552000.0 in 2025.
• Business Quant data shows PYXS's Change in Accured Expenses at $552000.0 in Q4 2025, $1.3 million in Q3 2025, and -$3.4 million in Q2 2025.